Skip to content
Search

Latest Stories

Submit Guest Post

Waste gasses from Tata Steel’s UK plant may power flights

INDIAN business conglomerate Tata, along with Neath Port Talbot council and LanzaTech, are moving ahead with a plan to use waste gasses from Tata's Port Talbot steel plant to power planes.

American bioengineering firm LanzaTech and Virgin Atlantic had worked together to fly from Orlando to London in 2018. The plane used recycled carbon jet fuel.


Waste gasses from the steel industry generate some 30 million gallons of biofuel for the aviation industry every year.

The US bioengineering firm’s gas fermentation process utilises carbon-rich industrial gases from steel production and turns them into ethanol.

Ethanol can then be converted into chemical products and fuel.

Neath Port Talbot council's deputy leader Anthony Taylor was quoted by BBC: "We accept Tata is one of the main carbon emitters across the whole of Wales. We don't want to endanger the economic side of things, but we have to tackle the environmental issues from this as well.”

"But also economically taking something that has previously been regarded as waste in the industrial process and actually harnessing it gives Tata Steel the opportunity to make some money from the waste it produces."

A Tata Steel spokesman said: "LanzaTech has the technology to transform waste CO2 from the steelmaking process into ethanol and is now seeking permission to develop a plant at our site in Port Talbot to convert that into jet fuel.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

AstraZeneca

AstraZeneca chief executive Pascal Soriot says the company has the science, pipeline and team to deliver its long-term growth ambitions

Getty Images

AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment

  • AstraZeneca expects its restructuring programme to generate $1.5bn in annualised savings by 2029, with most of the money reinvested in research and development.
  • The plan could incur up to $2bn in one-off restructuring costs, although the company expects its overall workforce to continue growing.
  • Third-quarter revenue rose 7 per cent to $16.21bn, while oncology sales increased 17 per cent to $7.77bn.

AstraZeneca has unveiled plans to generate around $1.5bn in annual savings through a three-year restructuring programme, as chief executive Pascal Soriot shifts the focus back to growth and investment in its drug pipeline.

The British-based pharmaceutical group said its Reshaping for Sustainable Growth programme would redirect resources towards research and development, particularly its pipeline of more than 180 projects and emerging technologies.

Keep ReadingShow less